630 related articles for article (PubMed ID: 8846043)
1. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
5. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
6. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
7. [Bone marrow changes in patients with hairy cell leukemia after 2-chlorodeoxyadenosine treatment].
Urasiński I; Zdziarska B; Krygier-Stojałowska A
Acta Haematol Pol; 1996; 27(1):49-55. PubMed ID: 8629443
[TBL] [Abstract][Full Text] [Related]
8. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
9. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
[TBL] [Abstract][Full Text] [Related]
11. Use of image analysis and immunostaining of bone marrow trephine biopsy specimens to quantify residual disease in patients with B-cell chronic lymphocytic leukemia.
Gala JL; Guiot Y; Delannoy A; Scheiff JM; Philippe M; Martiat P
Mod Pathol; 1999 Apr; 12(4):391-9. PubMed ID: 10229504
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.
Hakimian D; Tallman MS; Kiley C; Peterson L
Blood; 1993 Sep; 82(6):1798-802. PubMed ID: 7691237
[TBL] [Abstract][Full Text] [Related]
14. Effect of 2-chlorodeoxyadenosine therapy on bone marrow fibrosis in hairy cell leukemia.
Dedic K; Zák P
Neoplasma; 2004; 51(1):56-8. PubMed ID: 15004661
[TBL] [Abstract][Full Text] [Related]
15. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
Filleul B; Delannoy A; Ferrant A; Zenebergh A; Van Daele S; Bosly A; Doyen C; Mineur P; Glorieux P; Driesschaert P
Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
[TBL] [Abstract][Full Text] [Related]
16. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine.
Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K
Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671
[TBL] [Abstract][Full Text] [Related]
17. Assessment of complete remission after 2-chlorodeoxyadenosine for hairy cell leukemia: utility of marrow immunostaining and measurement of splenic index.
Tallman MS; Hakimian D; Dyrda S; Kiley C; Nemcek A; Peterson L
Leuk Lymphoma; 1994; 14 Suppl 1():133-8. PubMed ID: 7529609
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M
Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269
[TBL] [Abstract][Full Text] [Related]
19. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
Piro LD; Carrera CJ; Carson DA; Beutler E
N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Wheaton S; Tallman MS; Hakimian D; Peterson L
Blood; 1996 Feb; 87(4):1556-60. PubMed ID: 8608247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]